Polypill: Progress and Challenges to Global Use—Update on the Trials and Policy Implementation

Current Cardiology Reports

Volumn 17, Issue 12, 2015, Pages

  Webster, Ruth ^a   Rodgers, Anthony ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cardiovascular disease; Policy; Polypill; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; ATORVASTATIN; CANDESARTAN PLUS HYDROCHLOROTHIAZIDE PLUS ROSUVASTATIN; CARDIOVASCULAR AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLYPILL; RAMIPRIL; SIMVASTATIN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALSARTAN; VITAMIN D; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; MEDICATION COMPLIANCE; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; POLYPHARMACY; PREVENTIVE MEDICINE; PROGRAM ACCEPTABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG COMBINATION; DRUG EFFECTS; HEALTH CARE POLICY; PRACTICE GUIDELINE; PRIMARY PREVENTION; SECONDARY PREVENTION;

ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; HEALTH POLICY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SECONDARY PREVENTION;

EID: 84945260743     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-015-0673-x     Document Type: Review

References (32)

1. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.
2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
3. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
4. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121–37.
5. Kumar A, Fonarow GC, Eagle KA, et al. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH registry. Crit Pathways Cardiol. 2009;8:104–11.
6. Webster RJ, Heeley EL, Peiris DP, et al. Gaps in cardiovascular disease risk management in Australian general practice. Med J Austr. 2009;191:324–9.
7. Mendis S, Abegunde D, Yusuf S, et al. WHO study on prevention of recurrences of myocardial infarction and stroke (WHO-PREMISE). B World Health Organ. 2005;83:820–9.
8. Sharma KK, Gupta R, Agrawal A, et al. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India. Vasc Health Risk Manage. 2009;5:1007–14.
9. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet. 2011;378:1231–43.
10. World Health Organization. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. World Health Organization-Wellcome trust meeting report. Geneva; 2002.
11. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360:2–3.
12. World Health Organization. The World Health Report 2002: Reducing risks, promoting healthy life. Edited by: World Health Organization. Geneva; 2002.
13. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80 %. Br Med J. 2003;326:1419.
14. Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. Int J Clin Pract. 2010;64:1220–7.
15. Pill Collaborative Group, Rodgers A, Patel A, et al. An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. PLoS One. 2011;6:e19857.
16. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One. 2012;7:e41297. Results from a 12 week cross over RCT of polypill vs placebo in primary prevention.
17. Yusuf S, Pais P, Sigamani A, et al. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (Polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. Circulation. Cardiovasc Qual Outcome. 2012;5:463–71. Showed incremental improvement in risk factor reduction when full-dose polypill was used in patients at high CVD risk compared to low-dose polypill.
18. Indian Polycap S, Yusuf S, Pais P, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.[see comment]. Lancet. 2009;373:1341–51.
19. Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122:2078–88.
20. PolyIran. Available at http://clinicaltrials.gov/ct2/show/NCT01271985?term=polyiran&rank=1. Accessed July 2013
21. HOPE 3. Available at http://clinicaltrials.gov/ct2/show/NCT00468923?term=hope+3&rank=1. Accessed July 2013
22. TIPS 3. Available at http://clinicaltrials.gov/ct2/show/NCT01646437?term=tips+3&rank=1. Accessed July 2013
23. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA J Am Med Assoc. 2013;310:918–29. First large scale RCT of polypill vs usual care in secondary prevention of 2004 patients from Western Europe and India. Showed improvement in adherence, systolic blood pressure and LDL-cholesterol.
24. Patel A, Cass A, Peiris D et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prevent Cardiol. 2014. Randomised trial of polypill vs usual care in 623 Australian patients, including 50 % indigenous participants. Showed improvement in adherence to recommended CVD therapy.
25. Selak V, Elley CR, Bullen C et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348. Randomised trial of polypill vs usual care in 513 New Zealand patients, including 50 % Maori participants. Showed improvement in adherence to recommended CVD therapy.
26. Castellano JM, Sanz G, Penalvo JL et al. A polypill strategy to improve adherence: results from FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Project. J Am Coll Cardiol. 2014. Randomised trial of polypill vs components taken as individual medications. Showed improvement in adherence.
27. HOPE 4. Available at http://clinicaltrials.gov/ct2/show/NCT01826019?term=hope+4&rank=1. Accessed 10 October 2014
28. Virdee SK, Greenfield SM, Fletcher K, et al. Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. BMJ Open. 2013. doi:10.1136/bmjopen-2012-002498.
29. Viera AJ, Sheridan SL, Edwards T, et al. Acceptance of a polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med. 2011;52:10–5.
30. Steinberg G. Polypills: a new solution to help improve medication adherence. 2015. Available at https://news.aetna.com//polypills-new-solution-help-improve-medication-adherence/. Accessed 19th June 2015
31. Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet. 2007;370:2054–62.
32. World Health Organisation. Global action plan for the prevention and control of noncommunicable diseases. Geneva: World Health Organization; 2013.